

## Progress on the project against tuberculosis

LAUNCH IN ASIA AND AFRICA OF THE FIRST NUTRITIONAL SUPPLEMENT AGAINST TUBERCULOSIS, DEVELOPED BY THE BIOTECHNOLOGICAL COMPANY MANREMYC AND THAT REIG JOFRE WILL MARKET IN EUROPE



- Reig Jofre informs that Manremyc has signed an agreement with the SRS Life Sciences Pharmaceutical Group for marketing Nyaditum resae® in sixteen countries of Asia and Africa.
- Nyaditum resae® will be distributed in Europe by Reig Jofre.

Dr. Pere-Joan Cardona (left) with the president of SRS Life Sciences Group

**Barcelona, October 7, 2016.** The pharmaceutical company Reig Jofre reported in September 2015 the collaboration agreement signed with Manremyc, the biotechnological spin-off created from the Germans Trias i Pujol Health Sciences Research Institute (IGTP), for the marketing development in Europe of Nyaditum resae®, an innovative nutritional supplement against tuberculosis (TB).

Under the agreement signed with Manremyc, Reig Jofre will lead the development and marketing phases in Europe, including the incorporation of Nyaditum resae® as novel food in the European Food Safety Agency (EFSA), as well as its production at Reig Jofre's facilities.

Reig Jofre announces that as part of the international fair of the pharmaceutical industry CPHI Worldwide held this week in Barcelona, Manremyc has signed an agreement with the pharmaceutical group SRS Life Sciences based in Singapore and with presence in 77 countries, to market Nyaditum resae® in sixteen countries of Asia and Africa.



This nutritional supplement, the result of more than fifteen years of research led by Dr. Pere-Joan Cardona at IGTP, targets to reduce the risk of developing the disease in both people who carry the tuberculosis bacteria and those at risk of infection.

According to Dr. Cardona, CEO of Manremyc and director of the Experimental Tuberculosis Unit of IGTP, "*TB affects disadvantaged populations without access to certain medications. Nyaditum resae® intends to alleviate this situation by reaching over 5 million people at an affordable price through this agreement.*" In this regard, Manremyc project has been awarded the *certificate B-Corp* granted to companies with high social impact.

Also noteworthy that a study on the epidemiology of TB in big cities of Europe, published in the European scientific journal [www.eurosurveillance.org](http://www.eurosurveillance.org), highlighted that although TB notification rates are declining in most EU/ EEA countries, TB rates in big cities remain higher than the national averages, most likely as a result of the higher concentration of risk groups.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **[www.reigjofre.com](http://www.reigjofre.com)**

### **About Reig Jofre**

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the marketing and manufacture of own developments (RJF Pharma, approximately 79% of sales in 2015) and one of specialized contract development and manufacturing (RJF CDMO, 21% of sales in 2015). At its core activity, the company focuses on the development of technological-specialization products (beta-lactam antibiotics, injectable and freeze-dried products); therapeutic-specialization products in the areas of dermatology, respiratory/ENT and gynaecology; and food supplements and consumer healthcare. The company directs its R&D to develop new indications and/or dosage forms of already-known active ingredients, generic medicines with a special focus on the development of injectable, freeze-dried and generic beta-lactam antibiotics, topical dermatological products, OTCs and food supplements as well as the development of new innovative molecules in partnership with start-ups and biotech research centres.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF.  
Share capital: 63,214,220 shares.

### **For further information**

---



**Investors and analysts**

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com

**Media**

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com